Eflornithine

Throughout clinical trials data from a limited number of exposed pregnancies (22) indicate that there is no clinical evidence that treatment with eflornithine adversely affects mothers or foetuses. Among the 22 pregnancies that occurred during the trials, only 19 pregnancies occurred while the patient was using eflornithine. Of these 19 pregnancies, there were 9 healthy infants, 5 elective abortions, 4 spontaneous abortions and 1 birth defect (Down’s Syndrome to a 35 year old). To date, no other relevant epidemiological data are available. Animal studies have shown reproductive toxicity. The potential risk to humans is unknown. Therefore, women who are pregnant or planning pregnancy should use an alternative means to manage facial hair.

It is not known whether eflornithine/metabolites are excreted in human milk. Women should not use eflornithine whilst breastfeeding.

Fertility

There are no data available.

Eflornithine has no or negligible influence on the ability to drive and use machines.

The mostly skin related adverse reactions reported were primarily mild in intensity and resolved without discontinuation of eflornithine or initiation of medical treatment. The most frequently reported adverse reaction was acne, which was generally mild. In the vehicle controlled trials (n=596), acne was observed in 41% of patients at baseline; 7% of patients treated with eflornithine and 8% treated with vehicle experienced a worsening of their condition. Of those with no acne at baseline, similar percentages (14%) reported acne following treatment with eflornithine or vehicle.

The following listing notes the frequency of adverse skin reactions seen in clinical trials, according to MedDRA convention. MedDRA conventions for frequency are very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), or not known (cannot be estimated from the available data) including isolated reports. Note that over 1350 patients were treated with eflornithine in these trials for 6 months to one year, while only slightly more than 200 patients were treated with vehicle for 6 months. Most events were reported at similar rates between eflornithine and vehicle. The skin effects of burning, stinging, tingling, rash and erythema were reported at higher levels in eflornithine treated patients compared to vehicle, as indicated by the asterisk (*).

Frequency of adverse skin reactions seen in eflornithine clinical trials, (according to MedDRA frequency convention).

Skin and subcutaneous tissue disorders

Very common (≥1/10): Acne

Common (≥1/100 to <1/10): Pseudofolliculitis barbae, alopecia, stinging skin*, burning skin*, dry skin, pruritus, erythema*, tingling skin*, irritated skin, rash*, folliculitis

Uncommon (≥1/1,000 to <1/100): Ingrown hair, oedema face, dermatitis, oedema mouth, papular rash, bleeding skin, herpes simplex, eczema, cheilitis, furunculosis, contact dermatitis, abnormal hair texture and abnormal hair growth, hypopigmentation, flushing skin, lip numbness, skin soreness

Rare (≥1/10,000 to <1/1,000): Rosacea, seborrheic dermatitis, skin neoplasm, maculopapular rash, skin cysts, vesiculobullous rash, skin disorder, hirsutism, skin tightness

Paediatric population

The adverse reactions observed in adolescents are similar to the ones observed in adults.